Asset profile
R2R01
Biologic — subtype unspecified
Evidence outlook · lead readout
NCT06264310 · Heart Failure, Worsening Heart Failure (WHF)
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06264310: The study randomly assigned participants to R2R01 or placebo and used blinded treatment, but only 33 participants were enrolled across four groups. Its primary endpoint was safety and tolerability, and no primary-endpoint results or statistical comparison are posted, so the trial provides limited evidence at this time.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.